Eric Berthelet
Papers
4
Total Citations
505
H-Index
3
About
Eric Berthelet is a leading clinical researcher in head and neck oncology, with a primary focus on optimizing treatment strategies for oropharyngeal squamous cell carcinoma (OPSCC). He is best known as the principal investigator of the landmark ORATOR trial, a phase 2 randomized study that directly compared radiotherapy (RT) to transoral robotic surgery (TORS) for early-stage OPSCC. The initial results, published in 2019 and cited over 450 times, provided critical, high-level evidence in a field previously dominated by retrospective data, challenging assumptions about the superiority of surgical approaches. Berthelet’s work rigorously evaluated not only oncologic outcomes but also patient-reported quality of life and swallowing function, offering nuanced insights into treatment trade-offs. The final five-year results, released in 2024, further solidified the trial’s impact by confirming long-term survival and toxicity profiles. Beyond the ORATOR trial, his research addresses patient information needs during radiotherapy, demonstrating a commitment to patient-centered care. Through these contributions, Berthelet has shaped the evidence base guiding multidisciplinary decision-making for HPV-related oropharyngeal cancer, influencing clinical practice worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4